SynthesisEndocrine2026
Primary pancreatic paraganglioma: a systematic review.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic paraganglioma (P-PGL) is an exceptionally rare neuroendocrine tumor, often misdiagnosed as other pancreatic neoplasms due to overlapping clinical and radiological features. Evidence is limited to case reports and small series, and standardized diagnostic and therapeutic strategies are lacking.
objectiveTo systematically review published cases of P-PGL, summarizing clinical presentation, diagnostic approaches, management strategies, and outcomes.
methodsA systematic literature search was performed in major biomedical databases to identify reports of P-PGL with histological confirmation. Data regarding demographics, clinical and biochemical characteristics, imaging findings, treatment modalities, and follow-up were extracted and analyzed descriptively.
resultsA total of 50 cases were identified, predominantly in middle-aged adults, with a slight female predominance. Most tumors were non-functioning and incidentally discovered, although a subset presented with symptoms related to catecholamine excess. Imaging findings were heterogeneous and frequently indistinguishable from pancreatic neuroendocrine tumors. Surgical resection was the primary treatment in most cases and was associated with favorable outcomes. Malignant behavior was uncommon but reported. Long-term follow-up data were scarce.
conclusionsP-PGL is a rare entity with nonspecific clinical and radiological features, posing significant diagnostic challenges. Definitive diagnosis relies on histopathology and immunohistochemistry. Surgical resection appears to be the treatment of choice, with a generally good prognosis. Greater awareness and systematic reporting are needed to improve understanding of its natural history and optimal management.
Indexed as
Identifiers
42440163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.